Rose D W, Xiao S, Pillay T S, Kolch W, Olefsky J M
University of California at San Diego Department of Medicine, La Jolla 92093, USA.
Oncogene. 1998 Aug 20;17(7):889-99. doi: 10.1038/sj.onc.1201997.
Both p21ras and phosphatidylinositol 3-kinase (PI 3-k) are critical elements in signaling pathways mediating insulin/IGF-I induced cell cycle progression. For example, microinjection of antibodies, peptides, or recombinant proteins which block the interaction of the SH2 domains of the PI 3-k p85alpha subunit with tyrosine phosphorylated intracellular targets blocks insulin mediated DNA synthesis. We report here that this inhibitory phenotype is observed whether the injections are made into quiescent cells (the standard approach), or at any time point during G1 phase subsequent to stimulation. This observation is not true, however, for the major substrate of the insulin/IGF-I receptor (IRS-1) despite the well known interaction of p85 with IRS-1. Antibodies to IRS-1 are inhibitory only when injected during the first 15 min of G1 phase, as are antibodies to another major IRS-1 binding protein, the tyrosine phosphatase SHP2. We also have microinjected reagents which target proteins involved in the formation of rasGTP and which mediate some of the downstream effects of ras activation. Reagents which target the formation of rasGTP (Shc and dominant negative ras protein) inhibit DNA synthesis only at points early in G1, as do reagents which target components of the MAP kinase pathway. Injection of antibodies to p21ras itself, or a recombinant Raf-1 protein domain which binds to the effector region of ras in a GTP-dependent manner, results in the inhibition of cell cycle progression throughout G1 phase. The results point to a continuous requirement for both PI 3-k and ras activity until cellular commitment to DNA synthesis, although some of the molecules which are both upstream and downstream of these activities are only required transiently. Our results are also consistent with a Raf-1 independent ras activity late in G1, as well as IRS-1 independent effects of PI 3-kinase.
p21ras和磷脂酰肌醇3激酶(PI 3-k)都是介导胰岛素/胰岛素样生长因子-I(IGF-I)诱导细胞周期进程的信号通路中的关键元件。例如,显微注射能阻断PI 3-k p85α亚基的SH2结构域与酪氨酸磷酸化的细胞内靶点相互作用的抗体、肽或重组蛋白,可阻断胰岛素介导的DNA合成。我们在此报告,无论将注射物注入静止细胞(标准方法),还是在刺激后的G1期的任何时间点,都能观察到这种抑制表型。然而,对于胰岛素/IGF-I受体的主要底物(IRS-1)而言并非如此,尽管p85与IRS-1之间的相互作用是众所周知的。针对IRS-1的抗体仅在G1期的前15分钟内注射时具有抑制作用,另一种主要的IRS-1结合蛋白——酪氨酸磷酸酶SHP2的抗体也是如此。我们还显微注射了针对参与rasGTP形成且介导ras激活的一些下游效应的蛋白质的试剂。针对rasGTP形成的试剂(Shc和显性负性ras蛋白)仅在G1早期的时间点抑制DNA合成,针对丝裂原活化蛋白激酶(MAP)激酶途径组分的试剂也是如此。注射针对p21ras自身的抗体,或一种以GTP依赖方式结合到ras效应区的重组Raf-1蛋白结构域,会导致整个G1期细胞周期进程的抑制。这些结果表明,在细胞决定进行DNA合成之前,持续需要PI 3-k和ras的活性,尽管这些活性的一些上游和下游分子仅短暂需要。我们的结果还与G1晚期不依赖Raf-1的ras活性以及PI 3激酶不依赖IRS-1的效应一致。